Cardiac AI: The Billion Dollar Bet on Intervention Reduction

Cardiovascular AI: Why Reducing Interventions is the Only Metric That Matters

Healthcare systems are complex, and their costs are spiraling. For cardiovascular disease, the high cost and sheer volume of invasive procedures create a huge opening for AI-driven savings. Our diligence across the sector found a clear split: AI that proactively prevents the need for an intervention delivers a much better ROI than AI that just shaves time off existing workflows. This fundamentally changes patient care and the associated costs. Think about the raw numbers, a single percutaneous coronary intervention (PCI) can run over $20,000 and a coronary artery bypass graft (CABG) can top $50,000, so any AI platform that can prove it diverts patients from these big-ticket procedures is speaking directly to an investor’s biggest question: does the clinical evidence actually predict commercial success? Success here is measured by altering clinical pathways to reduce invasive interventions, not just achieving diagnostic accuracy. This approach is confirmed by the results from models like Hello Heart, which posted peer-reviewed $1,800 per-member savings and a 47% inpatient reduction, showing the very real financial outcomes of effective cardiovascular AI.

Real-Time Acute Event Detection: How Viz.ai Alters Care Pathways

Viz.ai’s initial product is a perfect example of a wedge that successfully alters acute care pathways. While many know them for their stroke AI, Viz.ai’s move into cardiac applications shows the clear trend towards real-time detection of acute cardiovascular events. The company’s backing is serious, it’s valued at $1.2B after a $100M Series D in April 2022 led by Tiger Global, with over $252 million raised in total. More importantly for investors, they’ve secured over 50 FDA-cleared AI care pathways for their algorithms. Viz.ai FDA 510(k) clearance documentation These clearances aren’t just paper. They are authority signals that de-risk the investment and signal market readiness. Viz.ai’s whole approach is about accelerating diagnosis and triage for things like pulmonary embolism and acute aortic syndromes. By analyzing medical images and alerting care teams faster than a human could, their SaMD reduces time-to-treatment, which can be the single factor that prevents a condition from escalating into something far more complex, costly, and invasive. For example, finding a large vessel occlusion in stroke faster means a faster thrombectomy, which can prevent the kind of long-term disability that costs the system millions over a patient’s lifetime. Applying this real-time detection model to cardiac events like an acute myocardial infarction holds the same promise. These platforms can flag subtle indicators that a radiologist might miss on a first read (or get to hours later), directly preventing the need for an emergent, high-cost cardiac intervention.

Precision Genomics: Tempus AI and Long-Term Intervention Reduction

Tempus AI is playing a different, longer game. In contrast to Viz.ai’s focus on acute events, this precision medicine company, which went public in June 2024 with a $12.8 billion market cap, is about preventing interventions over a patient’s lifetime. They’ve raised over $1 billion (including a $460 million post-IPO round in July 2026 backed by investors like GV) to build a massive proprietary genomic database and uses AI to sift through that clinical and molecular data. Tempus AI clinical partnership announcements That data is a competitive moat that lets them identify genetic predispositions and molecular signatures for building personalized treatment strategies. While it doesn’t stop a heart attack in real-time, the Tempus AI approach prevents costly future interventions by enabling earlier, more targeted therapies and proactive risk management. For instance, understanding a patient’s genetic profile can guide pharmacogenomic choices for cardiovascular drugs, reducing adverse reactions or simply making the treatment work better. We’ve already seen this work in oncology, their core business, where this precision has led to more effective, less toxic cancer treatments, preventing unnecessary surgeries or ineffective chemo rounds. Moving this genomic precision into cardiovascular disease, especially for inherited cardiomyopathies or even guiding stent selection with genetic markers, could dramatically reduce a person’s lifetime risk of needing invasive procedures by optimizing their long-term care. Yes, the ROI timeline is longer, but the potential to stop a cascade of future high-cost interventions is enormous.

The Pitfalls of Unfocused AI: The Cautionary Tale of Olive AI

The failure of Olive AI is a stark reminder for investors that not all healthcare AI is created equal. Despite raising an incredible $900 million (Tiger Global was a major backer here, too), Olive AI completely shut down. This massive destruction of capital teaches a critical lesson: not all AI in healthcare gives you a measurable ROI, especially when it’s not focused on direct clinical impact. Olive AI’s big idea was automating administrative tasks. Process optimization can be useful, but it just doesn’t produce the deep cost savings you get from preventing a high-cost clinical event. For investors, it’s critical to distinguish between AI that simplifies back-office work and AI that fundamentally changes patient outcomes to cut down on expensive procedures. The first might offer small efficiency gains, but it rarely delivers the kind of significant, verifiable ROI the second one can. The key is to evaluate platforms on their direct clinical impact and ability to change care pathways, not just their tech or funding. A lack of clear, peer-reviewed evidence showing intervention reduction, the kind of evidence Hello Heart has, should be a major red flag.

Investor Takeaway: Focus on Clinical Impact and Pathway Alteration

Investors have to look past the hype and evaluate these AI platforms on their direct clinical touchpoints and their proven ability to alter care pathways. The real metric for a cardiovascular AI platform is its capacity to reduce costly cardiac interventions, whether that’s through real-time event detection or long-term genomic profiling that guides proactive care. Our own benchmarking framework uses FDA clearance data, clinical utility studies, and a deep understanding of healthcare economics to spot high-impact clinical technologies. When you’re looking at a deal, you need to be asking tough questions.

• Does the SaMD have legitimate FDA 510(k) clearances or Breakthrough Device Designations for its cardiac applications, which signals it’s a serious, regulated product? FDA medical device databases
• Does the AI have a real data moat built on proprietary datasets that are hard to copy, giving it a performance edge?
• Is there any solid Real-World Evidence (RWE) or peer-reviewed clinical data showing it actually reduces high-cost cardiac interventions or shifts care to less invasive options?
• What’s the plan to manage algorithmic drift and make sure performance doesn’t degrade as real-world data changes?
• Does the company show strong GMLP compliance and have a certified QMS like ISO 13485, indicating they know how to build and maintain a medical-grade product?
• Is there a clear reimbursement path with existing CPT codes or NTAP potential, so that providers can actually get paid for using it?

The future of investment in this space is in solutions that reshape care delivery and directly attack the most expensive parts of the cardiac care chain. This framework, which we use to benchmark companies by analyzing FDA data, clinical studies, and financial outcomes, gets past the common chatter. Our data-driven approach helps us (and our clients) identify the high-impact clinical technologies, not just the slickly-marketed administrative tools.